KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Total Debt: 2011-2025

Historic Total Debt for Supernus Pharmaceuticals (SUPN) over the last 6 years, with Sep 2025 value amounting to $11.2 million.

  • Supernus Pharmaceuticals' Total Debt fell 75.88% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $135.2 million, marking a year-over-year decrease of 31.51%. This contributed to the annual value of $47.3 million for FY2024, which is 9.08% down from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Total Debt is $11.2 million, which was down 62.55% from $30.0 million recorded in Q1 2025.
  • Supernus Pharmaceuticals' Total Debt's 5-year high stood at $424.1 million during Q4 2021, with a 5-year trough of $11.2 million in Q3 2025.
  • Its 3-year average for Total Debt is $43.1 million, with a median of $46.9 million in 2024.
  • Over the last 5 years, Supernus Pharmaceuticals' Total Debt had its largest YoY gain of 1,603.17% in 2022, and its largest YoY loss of 95.02% in 2022.
  • Supernus Pharmaceuticals' Total Debt (Quarterly) stood at $424.1 million in 2021, then plummeted by 95.02% to $21.1 million in 2022, then surged by 146.54% to $52.1 million in 2023, then decreased by 9.08% to $47.3 million in 2024, then slumped by 75.88% to $11.2 million in 2025.
  • Its Total Debt was $11.2 million in Q3 2025, compared to $30.0 million in Q1 2025 and $47.3 million in Q4 2024.